Erythromycin

CHEMBL532 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
733.9 g/mol
LogP
2.7
Phase
4

This macrolide antibiotic works by blocking the bacterial ribosome so that bacteria cannot make the proteins they need to survive. It is used to treat a wide range of infections including respiratory, skin, and sexually transmitted infections.

分子量

733.9000 g/mol

LogP

2.70

TPSA

194.00 Ų

Lipinski 五规则

不符合

治疗领域

作用机制

Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1

Molecular Formula

C37H67NO13

HBD / HBA

5 / 14

可旋转键数

7

重原子数

51

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This macrolide antibiotic works by blocking the bacterial ribosome so that bacteria cannot make the proteins they need to survive. It is used to treat a wide range of infections including respiratory, skin, and sexually transmitted infections.

Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

Yes, Erythromycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL532. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 12560. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.